Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?

Company Performance - 89BIO (ETNB) has returned 10.5% year-to-date, outperforming the average gain of 7.4% for Medical stocks [4] - The Zacks Consensus Estimate for ETNB's full-year earnings has increased by 38% over the past quarter, indicating improving analyst sentiment [3] - Eton Pharmaceuticals, Inc. (ETON) has also shown strong performance with a year-to-date return of 13.9% and a consensus EPS estimate increase of 33.8% over the past three months [4][5] Industry Context - 89BIO is part of the Medical - Biomedical and Genetics industry, which consists of 510 companies and currently ranks 66 in the Zacks Industry Rank [6] - The average gain for the Medical - Biomedical and Genetics industry so far this year is 7.8%, with 89BIO outperforming this average [6] - The Medical group, which includes 1012 companies, is currently ranked 3 within the Zacks Sector Rank [2]